Intech Investment Management LLC Has $778,000 Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Intech Investment Management LLC increased its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 156.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,336 shares of the medical device company’s stock after buying an additional 11,173 shares during the period. Intech Investment Management LLC’s holdings in Tandem Diabetes Care were worth $778,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its position in shares of Tandem Diabetes Care by 5.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 38,732 shares of the medical device company’s stock worth $1,372,000 after purchasing an additional 1,985 shares in the last quarter. GAMMA Investing LLC boosted its position in Tandem Diabetes Care by 11.2% in the 2nd quarter. GAMMA Investing LLC now owns 4,276 shares of the medical device company’s stock valued at $172,000 after buying an additional 431 shares during the last quarter. LVW Advisors LLC increased its stake in shares of Tandem Diabetes Care by 15.1% in the 2nd quarter. LVW Advisors LLC now owns 7,869 shares of the medical device company’s stock valued at $317,000 after buying an additional 1,034 shares during the period. Diversified Trust Co raised its position in shares of Tandem Diabetes Care by 11.1% during the second quarter. Diversified Trust Co now owns 14,635 shares of the medical device company’s stock worth $590,000 after acquiring an additional 1,462 shares during the last quarter. Finally, ORG Partners LLC bought a new stake in shares of Tandem Diabetes Care during the second quarter worth $31,000.

Insider Buying and Selling at Tandem Diabetes Care

In related news, Director Kim D. Blickenstaff sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the transaction, the director now directly owns 195,190 shares of the company’s stock, valued at approximately $5,855,700. This represents a 4.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Stock Performance

Shares of TNDM stock opened at $30.63 on Friday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care, Inc. has a 52 week low of $18.45 and a 52 week high of $53.69. The company’s 50 day moving average price is $34.88 and its two-hundred day moving average price is $40.81. The company has a market capitalization of $2.01 billion, a P/E ratio of -15.87 and a beta of 1.36.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business had revenue of $243.97 million during the quarter, compared to the consensus estimate of $224.14 million. During the same period last year, the company earned ($0.38) earnings per share. Tandem Diabetes Care’s quarterly revenue was up 31.4% on a year-over-year basis. On average, analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Barclays lifted their price objective on Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. The Goldman Sachs Group assumed coverage on shares of Tandem Diabetes Care in a research report on Friday, October 4th. They set a “neutral” rating and a $46.00 price target for the company. Morgan Stanley restated an “equal weight” rating and issued a $45.00 price objective on shares of Tandem Diabetes Care in a report on Monday, September 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $55.00 target price (up previously from $50.00) on shares of Tandem Diabetes Care in a report on Friday, August 2nd. Finally, Canaccord Genuity Group cut their price target on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $54.25.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.